Meningioma

Referências

Principais artigos

Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016 Jun;131(6):803-20.Texto completo  Resumo

Claus EB, Bondy ML, Schildkraut JM, et al. Epidemiology of intracranial meningioma. Neurosurgery. 2005;57:1088-1095. Resumo

Harrison MJ, Wolfe DE, Lau TS, et al. Radiation-induced meningiomas: experience at the Mount Sinai Hospital and review of the literature. J Neurosurg. 1991;75:564-574. Resumo

Antinheimo J, Sankila R, Carpen O, et al. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology. 2000;54:71-76. Resumo

Kan P, Simonsen SE, Lyon JL, et al. Cellular phone use and brain tumor: a meta-analysis. J Neurooncol. 2008;86:71-78. Resumo

Sughrue ME, Rutkowski MJ, Aranda D, et al. Treatment decision making based on the published natural history and growth rate of small meningiomas. J Neurosurg. 2010;113:1036-1042. Resumo

Goldbrunner R, Minniti G, Preusser M, et al. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol. 2016 Sep;17(9):e383-91.Texto completo  Resumo

Kondziolka D, Levy EI, Niranjan A, et al. Long-term outcomes after meningioma radiosurgery: physician and patient perspectives. J Neurosurg. 1999;91:44-50. Resumo

Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 1957;20:22-39. Resumo

Claus EB, Black PM, Bondy ML, et al. Exogenous hormone use and meningioma risk: what do we tell our patients? Cancer. 2007;110:471-476.Texto completo  Resumo

Artigos de referência

1. Ostrom QT, Gittleman H, Farah P, et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol. 2013;15(suppl 2):ii1-ii56. [Erratum in: Neuro Oncol. 2014;16:760.]Texto completo  Resumo

2. Louis DN, Ohgaki H, Wiestler OD, et al (eds). World Health Organization classification of tumours of the central nervous system. Revised, 4th edition. France: IARC; 2016.

3. Rogers L, Gilbert M, Vogelbaum MA. Intracranial meningiomas of atypical (WHO grade II) histology. J Neurooncol. 2010;99:393-405. Resumo

4. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016 Jun;131(6):803-20.Texto completo  Resumo

5. Claus EB, Bondy ML, Schildkraut JM, et al. Epidemiology of intracranial meningioma. Neurosurgery. 2005;57:1088-1095. Resumo

6. Longstreth WT, Jr, Dennis LK, McGuire VM, et al. Epidemiology of intracranial meningioma. Cancer. 1993;72:639-648.Texto completo  Resumo

7. Benson VS, Pirie K, Green J, et al. Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort. Br J Cancer. 2008;99:185-190.Texto completo  Resumo

8. Harrison MJ, Wolfe DE, Lau TS, et al. Radiation-induced meningiomas: experience at the Mount Sinai Hospital and review of the literature. J Neurosurg. 1991;75:564-574. Resumo

9. Mack EE, Wilson CB. Meningiomas induced by high-dose cranial irradiation. J Neurosurg. 1993;79:28-31. Resumo

10. Shintani T, Hayakawa N, Hoshi M, et al. High incidence of meningioma among Hiroshima atomic bomb survivors. J Radiat Res (Tokyo). 1999;40:49-57.Texto completo  Resumo

11. Paulino AC, Ahmed IM, Mai WY, et al. The influence of pretreatment characteristics and radiotherapy parameters on time interval to development of radiation-associated meningioma. Int J Radiat Oncol Biol Phys. 2009;75:1408-1414. Resumo

12. Ragel BT, Jensen RL, Couldwell WT. Inflammatory response and meningioma tumorigenesis and the effect of cyclooxygenase-2 inhibitors. Neurosurg Focus. 2007;23:E7.Texto completo  Resumo

13. Ragel BT, Jensen RL, Gillespie DL, et al. Celecoxib inhibits meningioma tumor growth in a mouse xenograft model. Cancer. 2007;109:588-597.Texto completo  Resumo

14. Ron E, Modan B, Boice JD, Jr, et al. Tumors of the brain and nervous system after radiotherapy in childhood. N Engl J Med. 1988;319:1033-1039. Resumo

15. Preston-Martin S, Henderson BE, Bernstein L. Medical and dental x rays as risk factors for recently diagnosed tumors of the head. Natl Cancer Inst Monogr. 1985;69:175-179. Resumo

16. Hemminki K, Li X, Collins VP. Parental cancer as a risk factor for brain tumors (Sweden). Cancer Causes Control. 2001;12:195-199. Resumo

17. Antinheimo J, Sankila R, Carpen O, et al. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology. 2000;54:71-76. Resumo

18. Watson MA, Gutmann DH, Peterson K, et al. Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays. Am J Pathol. 2002;161:665-672.Texto completo  Resumo

19. Custer BS, Koepsell TD, Mueller BA. The association between breast carcinoma and meningioma in women. Cancer. 2002;94:1626-1635.Texto completo  Resumo

20. Jhawar BS, Fuchs CS, Colditz GA, et al. Sex steroid hormone exposures and risk for meningioma. J Neurosurg. 2003;99:848-853. Resumo

21. Wrensch M, Minn Y, Chew T, et al. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol. 2002;4:278-299.Texto completo  Resumo

22. Phillips LE, Koepsell TD, van Belle G, et al. History of head trauma and risk of intracranial meningioma: population-based case-control study. Neurology. 2002;58:1849-1852. Resumo

23. Ragel BT, Couldwell WT, Wurster RD, et al. Chronic suppressive therapy with calcium channel antagonists for refractory meningiomas. Neurosurg Focus. 2007;23:E10.Texto completo  Resumo

24. Strojan P, Popović M, Jereb B. Secondary intracranial meningiomas after high-dose cranial irradiation: report of five cases and review of the literature. Int J Radiat Oncol Biol Phys. 2000;48:65-73. Resumo

25. Kan P, Simonsen SE, Lyon JL, et al. Cellular phone use and brain tumor: a meta-analysis. J Neurooncol. 2008;86:71-78. Resumo

26. Coureau G, Bouvier G, Lebailly P, et al. Mobile phone use and brain tumours in the CERENAT case-control study. Occup Environ Med. 2014;71:514-522. Resumo

27. Kernick DP, Ahmed F, Bahra A, et al. Imaging patients with suspected brain tumour: guidance for primary care. Br J Gen Pract. 2008;58:880-885.Texto completo  Resumo

28. Ownsworth T, Hawkes A, Steginga S, et al. A biopsychosocial perspective on adjustment and quality of life following brain tumor: a systematic evaluation of the literature. Disabil Rehabil. 2009;31:1038-1055. Resumo

29. Nakasu S, Fukami T, Nakajima M, et al. Growth pattern changes of meningiomas: long-term analysis. Neurosurgery. 2005;56:946-955. Resumo

30. Oya S, Kim SH, Sade B, et al. The natural history of intracranial meningiomas. J Neurosurg. 2011;114:1250-1256.Texto completo  Resumo

31. Louis D, Scheithauer B, Budka H, et al. Meningiomas. In: Kleihues P, Cavenee W, editors. World Health Organization classification of tumours: pathology and genetics: tumours of the nervous system. Lyon, France: IARC Press, 2000.

32. Louis DN, Ohgaki H, Westler OD, et al (eds). World Health Organization classification of tumours of the central nervous system. Lyon, France: IARC; 2007.

33. Nakamura M, Roser F, Michel J, et al. The natural history of incidental meningiomas. Neurosurgery. 2003;53:62-70. Resumo

34. Komotar RJ, Starke RM, Raper DM, et al. Endoscopic endonasal versus open transcranial resection of anterior midline skull base meningiomas. World Neurosurg. 2012;77:713-724. Resumo

35. Kotecha RS, Pascoe EM, Rushing EJ, et al. Meningiomas in children and adolescents: a meta-analysis of individual patient data. Lancet Oncol. 2011;12:1229-1239. Resumo

36. Sughrue ME, Rutkowski MJ, Aranda D, et al. Treatment decision making based on the published natural history and growth rate of small meningiomas. J Neurosurg. 2010;113:1036-1042. Resumo

37. Firsching RP, Fischer A, Peters R, et al. Growth rate of incidental meningiomas. J Neurosurg. 1990;73:545-547. Resumo

38. Go RS, Taylor BV, Kimmel DW. The natural history of asymptomatic meningiomas in Olmsted County, Minnesota. Neurology. 1998;51:1718-1720. Resumo

39. Herscovici Z, Rappaport Z, Sulkes J, et al. Natural history of conservatively treated meningiomas. Neurology. 2004;63:1133-1134. Resumo

40. Olivero WC, Lister JR, Elwood PW. The natural history and growth rate of asymptomatic meningiomas: a review of 60 patients. J Neurosurg. 1995;83:222-224. Resumo

41. Yano S, Kuratsu J. Indications for surgery in patients with asymptomatic meningiomas based on an extensive experience. J Neurosurg. 2006;105:538-543. Resumo

42. Yoneoka Y, Fujii Y, Tanaka R. Growth of incidental meningiomas. Acta Neurochir (Wien). 2000;142:507-511. Resumo

43. Goldbrunner R, Minniti G, Preusser M, et al. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol. 2016 Sep;17(9):e383-91.Texto completo  Resumo

44. Marcus HJ, Price SJ, Wilby M, et al. Radiotherapy as an adjuvant in the management of intracranial meningiomas: are we practising evidence-based medicine? Br J Neurosurg. 2008;22:520-528. Resumo

45. Clark AJ, Jahangiri A, Garcia RM, et al. Endoscopic surgery for tuberculum sellae meningiomas: a systematic review and meta-analysis. Neurosurg Rev. 2013;36:349-359. Resumo

46. Sughrue ME, Rutkowski MJ, Aranda D, et al. Factors affecting outcome following treatment of patients with cavernous sinus meningiomas. J Neurosurg. 2010;113:1087-1092. Resumo

47. Jaaskelainen J, Haltia M, Servo A. Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol. 1986;25:233-242. Resumo

48. Rosenthal MA, Ashley DL, Cher L. Treatment of high risk or recurrent meningiomas with hydroxyurea. J Clin Neurosci. 2002;9:156-158. Resumo

49. Wen PY, Schiff D, Kesari S, et al. Medical management of patients with brain tumors. J Neurooncol. 2006;80:313-332. Resumo

50. Kondziolka D, Levy EI, Niranjan A, et al. Long-term outcomes after meningioma radiosurgery: physician and patient perspectives. J Neurosurg. 1999;91:44-50. Resumo

51. Schrell UM, Rittig MG, Anders M, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. J Neurosurg. 1997;86:845-852. Resumo

52. Schrell UM, Rittig MG, Anders M, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg. 1997;86:840-844. Resumo

53. Weston GJ, Martin AJ, Mufti GJ, et al. Hydroxyurea treatment of meningiomas: a pilot study. Skull Base. 2006;16:157-160.Texto completo  Resumo

54. Newton HB, Slivka MA, Stevens C. Hydroxyurea chemotherapy for unresectable or residual meningioma. J Neurooncol. 2000;49:165-170. Resumo

55. Newton HB, Scott SR, Volpi C. Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up. Br J Neurosurg. 2004;18:495-499. Resumo

56. Loven D, Hardoff R, Sever ZB, et al. Non-resectable slow-growing meningiomas treated by hydroxyurea. J Neurooncol. 2004;67:221-226. Resumo

57. Gupta V, Su YS, Samuelson CG, et al. Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas. J Neurosurg. 2007;106:455-462. Resumo

58. Chamberlain MC, Tsao-Wei DD, Groshen S. Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol. 2006;78:271-276. Resumo

59. de Robles P, McIntyre J, Kalra S, et al. Methylation status of MGMT gene promoter in meningiomas. Cancer Genet Cytogenet. 2008;187:25-27. Resumo

60. Sherman WJ, Raizer JJ. Chemotherapy: What is its role in meningioma? Expert Rev Neurother. 2012;12:1189-1196.Texto completo  Resumo

61. Chamberlain MC. Adjuvant combined modality therapy for malignant meningiomas. J Neurosurg. 1996 May;84(5):733-6. Resumo

62. Preusser M, Spiegl-Kreinecker S, Lötsch D, et al. Trabectedin has promising antineoplastic activity in high-grade meningioma. Cancer. 2012;118:5038-5049.Texto completo  Resumo

63. Ji Y, Rankin C, Grunberg S, et al. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol. 2015;33:4093-4098. Resumo

64. Goodwin JW, Crowley J, Eyre HJ, et al. A Phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol. 1993;15:75-77. Resumo

65. Schulz S, Pauli SU, Handel M, et al. Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res. 2000;6:1865-1874.Texto completo  Resumo

66. Schulz C, Mathieu R, Kunz U, et al. Treatment of unresectable skull base meningiomas with somatostatin analogs. Neurosurg Focus. 2011;30:E11. Resumo

67. Chamberlain MC, Glantz MJ, Fadul CE. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology. 2007;69:969-973. Resumo

68. Arena S, Barbieri F, Thellung S, et al. Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. J Neurooncol. 2004;66:155-166. Resumo

69. Simó M, Argyriou AA, Macià M, et al. Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy. Cancer Chemother Pharmacol. 2014;73:919-923. Resumo

70. Kaba SE, DeMonte F, Bruner JM, et al. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery. 1997;40:271-275. Resumo

71. Koper JW, Zwarthoff EC, Hagemeijer A, et al. Inhibition of the growth of cultured human meningioma cells by recombinant interferon-alpha. Eur J Cancer. 1991;27:416-419. Resumo

72. Wober-Bingol C, Wober C, Marosi C, et al. Interferon-alfa-2b for meningioma. Lancet. 1995;345:331. Resumo

73. Chamberlain MC, Glantz MJ. Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer. 2008;113:2146-2151.Texto completo  Resumo

74. Mason WP, Gentili F, Macdonald DR, et al. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg. 2002;97:341-346. Resumo

75. Machein MR, Plate KH. VEGF in brain tumors. J Neurooncol. 2000;50:109-120. Resumo

76. Preusser M, Hassler M, Birner P, et al. Microvascularization and expression of VEGF and its receptors in recurring meningiomas: pathobiological data in favor of anti-angiogenic therapy approaches. Clin Neuropathol. 2012;31:352-360. Resumo

77. Nayak L, Iwamoto FM, Rudnick JD, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol. 2012;109:187-193. Resumo

78. Lou E, Sumrall AL, Turner S, et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol. 2012;109:63-70.Texto completo  Resumo

79. Andrae N, Kirches E, Hartig R, et al. Sunitinib targets PDGF-receptor and Flt3 and reduces survival and migration of human meningioma cells. Eur J Cancer. 2012;48:1831-1841.Texto completo  Resumo

80. Kaley TJ, Wen P, Schiff D, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2014 Aug 6. [Epub ahead of print.] Resumo

81. Raheja A, Colman H, Palmer CA, et al. Dramatic radiographic response resulting in cerebrospinal fluid rhinorrhea associated with sunitinib therapy in recurrent atypical meningioma: case report. J Neurosurg. 2017 Nov;127(5):965-970. Resumo

82. Raizer JJ, Grimm SA, Rademaker A, et al. A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas. J Neurooncol. 2014 Mar;117(1):93-101. Resumo

83. Mirimanoff RO, Dosoretz DE, Linggood RM, et al. Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg. 1985;62:18-24. Resumo

84. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 1957;20:22-39. Resumo

85. Milker-Zabel S, Zabel A, Schulz-Ertner D, et al. Fractionated stereotactic radiotherapy in patients with benign or atypical intracranial meningioma: long-term experience and prognostic factors. Int J Radiat Oncol Biol Phys. 2005;61:809-816. Resumo

86. Sanai N, Sughrue ME, Shangari G, et al. Risk profile associated with convexity meningioma resection in the modern neurosurgical era. J Neurosurg. 2010;112:913-919. Resumo

87. Diluna ML, Bulsara KR. Surgery for petroclival meningiomas: a comprehensive review of outcomes in the skull base surgery era. Skull Base. 2010;20:337-342. Resumo

88. Tremont-Lukats IW, Ratilal BO, Armstrong T, et al. Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database Syst Rev. 2008;(2):CD004424. Resumo

89. Couldwell WT. Asymptomatic meningiomas. J Neurosurg. 2006;105:536-537. Resumo

90. Claus EB, Black PM, Bondy ML, et al. Exogenous hormone use and meningioma risk: what do we tell our patients? Cancer. 2007;110:471-476.Texto completo  Resumo

91. Lall RR, Lall RR, Smith TR, et al. Delayed malignant transformation of petroclival meningioma to chondrosarcoma after stereotactic radiosurgery. J Clin Neurosci. 2014;21:1225-1228. Resumo

92. Osipov V, Ho KC, Krouwer HG, et al. Post-radiation dedifferentiation of meningioma into osteosarcoma. BMC Cancer. 2002;2:34.Texto completo  Resumo

93. Rogers L, Barani I, Chamberlain M, et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg. 2014 Oct 24. [Epub ahead of print.] Resumo

O uso deste conteúdo está sujeito ao nosso aviso legal